Reactivation of mutant p53: A new strategy for cancer therapy

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 369-378

  Selivanova, Galina ^b   Kawasaki, Takashi ^b   Ryabchenko, Ludmila ^b   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

C terminus; Cancer therapy; Mutant p53; p53 regulation; Reactivation

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN P53;

APOPTOSIS; BINDING AFFINITY; CANCER INHIBITION; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; DNA BINDING; GENE ACTIVATION; GENE MUTATION; MISSENSE MUTATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL PROCESSING; TRANSACTIVATION;

EID: 0000449082     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0099     Document Type: Article

References (70)

1. 1. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
2. 2. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
3. 3. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
4. 4. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002
5. 5. Caelics C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223
6. 6. Wagner AJ, Kokontis JM, Hay N (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 8:2817-2830
7. 7. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9:2170-2183
8. 8. Bennett M, Macdonald K, Chan S, Luzio JP, Simari R, Weissberg P (1998) Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 282:290-293
9. 9. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355
10. 10. Béroud C, Soussi T (1998) p53 gene mutation: software and database. Nucl Acids Res 26:200-204
11. 11. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C (1993) A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565-2574
12. 12. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB (1994) A temperature-sensitive mutant of human p53. EMBO J 13:2535-2544
13. 13. Michalovitz D, Halevy O, Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680
14. 14. Hupp TR, Meek DW, Midgley CA, Lane DP (1993) Activation of the cryptic DNA binding function of mutant forms of p53. Nucl Acids Res 21:3167-3174
15. 15. Halazonetis TD, Kandil AN (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12:5057-5064
16. 16. Niewolik D, Vojtesek B, Kovarik J (1995) p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881-890
17. 17. Abarzúa P, LoSardo JE, Gubler ML, Neri A (1995) Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 55:3490-3494
18. 18. Abarzúa P, LoSardo JE, Gubler ML, Spathis R, Lu YA, Felix A, Neri A (1996) Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13:2477-2482
19. 19. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 3:632-638
20. 20. Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD (1996) Structure-based rescue of common tumor-derived p53 mutants. Nature Med 2:1143-1146
21. 21. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD (1998) Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17:1847-1859
22. 22. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
23. 23. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
24. 24. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886
25. 25. Haapajarvi T, Pitkanen K, Tsubari M, Laiho M (1997) p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. Mol Cell Biol 17:3074-3080
26. 26. Chernov MV, Ramana CV, Adler W, Stark GR (1998) Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc Natl Acad Svi USA 95:2284-2289
27. 27. Hupp TR, Sparks A, Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245
28. 28. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PWK (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704
29. 29. Milner J (1994) Forms and functions of p53. Semin Cancer Biol 5:211-219
30. 30. Hupp TR, Lane DP (1994) Allosteric activation of latent p53 tetramers. Curr Biol 4:865-875
31. 31. Hupp TR, Lane DP (1995) Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase H independent manner. J Biol Chem 270: 18165-18174
32. 32. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet 19:175-178
33. 33. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334
34. 34. Kapoor M, Lozano G (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 95:2834-2837
35. 35. Shaw P, Freeman J, Bovey R, Iggo R (1996) Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921-930
36. 36. Wang Y, Prives C (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376:88-91
37. 37. Bayle JH, Elenbaas B, Levine AJ (1995) The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its non-specific nucleic acid-binding activity. Proc Natl Acad Sci USA 92:5729-5733
38. 38. Anderson ME, Woelker B, Reed M, Wang P, Tegtmeyer P (1997) Reciprocal interference between the sequence-specific core and non-specific C-terminal DNA binding domains of p53: implications for regulation. Mol Cell Biol 17:6255-6264
39. 39. Waterman JL, Shenk JL, Halazonetis TD (1995) The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J 14:512-519
40. 40. Müller-Tiemann BF, Halazonetis TD, Elting JJ (1998) Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc Natl Acad Sci USA 95:6079-6084
41. 41. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10455
42. 42. Freeman J, Schmidt S, Scharer E, Iggo R (1994) Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J 13:5393-5400
43. 43. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455
44. 44. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-542
45. 45. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16:3269-3277
46. 46. Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317-1322
47. 47. Takenaka I, Morin F, Seizinger BR, Kley N (1995) Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270:5405-5411
48. MAT1-dependent manner. Mol Cell Biol 17:7220-7229
49. 49. Lu H, Fisher RP, Bailey P, Levine AJ (1997) The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 17:5923-5934
50. 50. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606
51. 51. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841
52. 52. Jayaraman L, Murthy KGK, Zhu C, Curran T, Xan-Thoudakis S, Prives C (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11:558-570
53. 53. Meira LB, Cheo DL, Hammer RE, Burns DK, Reis A, Friedberg EC (1997) Genetic interaction between HAP1/REF-1 and p53. Nature Genet 17:145
54. 54. Drane P, Barel M, Balbo M, Frade R (1997) Identification of RB18A, a 205-kDa new p53 regulatory protein which shares antigenic and functional properties with p53. Oncogene 15:3013-3024
55. ING1 cooperates with p53 in cell growth control. Nature 391:295-298
56. 56. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721
57. 57. Ouchi T, Monteiro ANA, August A, Aaronson SA, Hanafusa H (1998) BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:2302-2306
58. 58. Vaziri H, West MD, Allsopp RC, Davison TS, Wu Y, Arrowsmith CH, Poirier GG, Benchimol S (1997) ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 19:6018-6033
59. 59. Malanga M, Pleschke JM, Kleczkowska HE, Althaus FR (1998) Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. J Biol Chem 19:11839-11843
60. 60. Jayaraman IL, Moorthy NC, Murthy KGK, Manley JL, Bustin M, Prives C (1998) High mobility group protein-1 (HMG1) is a unique activator of p53. Genes Dev 12:462-472
61. 61. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392:405-408
62. 62. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827
63. 63. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184
64. 64. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso LL, Moran E, Berger SL, Halazonetis TD (1997) CREB-binding protein and p300/CBIP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 57:3693-3696
65. 65. Jayaraman L, Prives C (1995) Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029
66. 66. Selivanova G, Iotsova V, Kiseleva E, Strom M, Bakalkin G, Grafstrom RC, Wiman KG (1996) The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucl Acids Res 24:3560-3567
67. 67. Kulesz-Martin MF, Lisafeld B, Huang H, Kisiel ND, Lee L (1994) Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 14:1698-1708
68. 68. Wolkowicz R, Peled A, Elkind NB, Rotter V (1995) Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc Natl Acad Sci USA 92:6842-6846
69. 69. Wu L, Bayle JH, Elenbaas B, Pavietich NP, Levine AJ (1995) Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 15:497-504
70. 70. Chen X, Ko W, Jayaraman IL, Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438-2451